Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy [ESPRIT] trial)

American Journal of Cardiology

Volumn 90, Issue 6, 2002, Pages 585-590

  Labinaz, Marino ^a   Madan, Mina ^b   O'Shea, J Conor ^c   Kilaru, Rakhi ^c   Chin, Wai ^c   Pieper, Karen ^c   McGuire, Darren K ^d   Saucedo, Jorge F ^e   Talley, J David ^e   Lui, Henry ^f   Kitt, Michael M ^g   Califf, Robert M ^c   Tcheng, James E ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^f Jackson Madison County General Hospital   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; INSULIN; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037106945     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02560-2     Document Type: Article

References (19)

1. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
2. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators, Lincoff A.M., Califf R.M., Moliterno D.J., Ellis S.G., Ducas J., Kramer J.H., Kleiman N.S., Cohen E.A., Booth J.E., Sapp S.K., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
3. Topol E., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M.E., Neumann F.J., Stone G.W., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894.
4. The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Evaluation of Platelet IIb/IIIa Inhibitor for Stenting . Lancet. 352:1998;87-92.
5. O'Shea J.C., Hafley G.E., Greenberg S., Hasselblad V., Lorenz T.J., Kitt M.M., Strony J., Tcheng J.E. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial a randomized controlled trial . JAMA. 285:2001;2468-2473.
6. Tschoepe D., Roesen P., Kaufmann L., Schauseil S., Kehrel B., Ostermann H., Gries F.A. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 20:1990;166-170.
7. Mandal S., Sarode R., Dash S., Dash R.J. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. Am J Clin Pathol. 100:1993;103-107.
8. Marso S.P., Lincoff A.M., Ellis S., Bhatt D.L., Tanguay J.F., Kleiman N.S., Hammoud T., Booth J.E., Sapp S.K., Topol E.J. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy . Circulation. 100:1999;2477-2484.
9. Aronson D., Bloomgarden Z., Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 27:1996;528-535.
10. Kornowski R., Mintz G.S., Kent K.M., Pichard A.D., Satler L.F., Bucher T.A., Hong M.K., Popma J.J., Leon M.B. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia A serial intravascular ultrasound study . Circulation. 95:1997;1366-1369.
11. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R.J., George B.S., Fintel D., Weston M., EPIC Investigators . Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis results at six months. The EPIC Investigators . Lancet. 343:1994;881-886.
12. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 35:2000;922-928.
13. The TARGET Investigators . TARGET 6-month results: tirofiban catching up . Accessed on August 6, 2001.
14. Chandrasekar B., Tanguay J.F. Platelets and restenosis. J Am Coll Cardiol. 35:2000;555-562.
15. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
16. Topol E.J., Ferguson J.J., Weisman H.F., Tcheng J.E., Ellis S.G., Kleiman N.S., Ivanhoe R.J., Wang A.L., Miller D.P., Anderson K.M., Califf R.M. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication . JAMA. 278:1997;479-484.
17. The ERASER Investigators . Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 100:1999;799-806.
18. Kleiman N.S., Lincoff A.M., Kereiakes D.J., Miller D., Aguirre F.V., Anderson K.M., Weisman H.F., Califf R.M., Topol E.J. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin evidence for a complex interaction in a multicenter trial. EPILOG Investigators . Circulation. 97:1998;1912-1920.
19. Velianou J., Mathew V., Wilson S., Barsness G.W., Grill D.E., Holmes D.R. Jr. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation. Am J Cardiol. 86:2000;1063-1068.